Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
Provided are methods and compositions for identifying a miRNA profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient.
1. A method of treating a patient that has pancreatic ductal adenocarcinoma (PDAC) comprising:
a) measuring by reverse-transcriptase polymerase chain reaction (RT-PCR) from a fine needle aspirate (FNA) pancreatic sample from the patient the level of expression of up to 11 different miRNAs that include at least miR-135b and at least 4 of the following diff pair miRNAs: miR148a, miR-130b, miR-196a, miR-24, miR-375, and miR-96, wherein at least one of the miRNAs is a biomarker miRNA and one is a comparative miRNA and miR-217 is not one of the miRNAs;
b) determining a diff pair value for diff pairs: miR135b/miR-24, miR130b/miR-135b; miR-135b/miR-148a; miR-148a/miR-196a; miR-135b/miR-96; miR-375/miR-135b and optionally miR-130b/miR-24 and,
c) analyzing the diff pair values using a computer performing linear discriminate analysis, wherein the linear discriminate identifies the patient as having PDAC; and
d) treating the identified patient with chemotherapy, radiotherapy, surgery, or immunotherapy to treat the PDAC.
2. The method of claim 1 , wherein the levels of at most 7 different miRNAs are measured.
3. The method of claim 1 , further comprising wherein the sample has undergone a cytology analysis prior to measuring the level of expression of any miRNA.
4. The method of claim 1 , wherein the treating comprises administering to the identified patient identified chemotherapy.
5. The method of claim 1 , wherein the treating comprises administering to the identified patient identified immunotherapy.